Michael Gould to Anticoagulants
This is a "connection" page, showing publications Michael Gould has written about Anticoagulants.
Connection Strength
0.924
-
The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study. J Hosp Med. 2023 01; 18(1):43-54.
Score: 0.204
-
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999 May 18; 130(10):789-99.
Score: 0.160
-
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999 May 18; 130(10):800-9.
Score: 0.160
-
Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials. 2014 Dec 20; 15:502.
Score: 0.118
-
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. JAMA. 2014 Nov 26; 312(20):2135-45.
Score: 0.117
-
Preventing venous thromboembolism in the intensive care unit: A no-brainer? J Crit Care. 2005 Dec; 20(4):304-5.
Score: 0.063
-
Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. Blood Adv. 2020 06 23; 4(12):2557-2566.
Score: 0.043
-
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. J Arthroplasty. 2017 11; 32(11):3524-3528.e1.
Score: 0.035
-
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e419S-e496S.
Score: 0.024